Dr. Pablo Lores Lareo, PhDCMC Director at SylentisSpeaker
Profile
CMC Director at Sylentis, a leading European based CDMO with 20 years’ experience in the development and manufacturing of therapeutic oligonucleotides. I combine my extensive technical leadership in development, process validation, and manufacturing, with strategic regulatory and business development to help drive innovative oligonucleotide-based therapies to patients.
Agenda Sessions
Phase- appropriate CMC Considerations for Next-generation Oligonucleotides
, 11:15amView SessionLessons Learned Building an Oligo CMC Program for a Small Company: Doing More with Less
, 4:45pmView Session